The endoplasmic reticulum (ER) is responsible for the synthesis of secretory and membrane proteins, which acquire folding into their lowest energy structures within this organelle. Perturbations of ER homeostasis can create a condition referred to as ER stress, which is marked by activation of a group of complex signaling pathways called the unfolded protein response (UPR) [1] [2] [3] [4] . Two type I transmembrane kinases (PKR-like ER kinase (PERK) and inositol-requiring enzyme 1 (IRE1)), plus a specific type II transmembrane protein (activating transcription factor 6 (ATF6)), have major roles in initiating UPR signaling [1] [2] [3] [4] .
The endoplasmic reticulum (ER) is responsible for the synthesis of secretory and membrane proteins, which acquire folding into their lowest energy structures within this organelle. Perturbations of ER homeostasis can create a condition referred to as ER stress, which is marked by activation of a group of complex signaling pathways called the unfolded protein response (UPR) [1] [2] [3] [4] . Two type I transmembrane kinases (PKR-like ER kinase (PERK) and inositol-requiring enzyme 1 (IRE1)), plus a specific type II transmembrane protein (activating transcription factor 6 (ATF6)), have major roles in initiating UPR signaling [1] [2] [3] [4] .
Of these three transmembrane proteins, IRE1 is most conserved evolutionarily. In addition to its kinase activity, IRE1 also has endoRNase activity 5, 6 and one of its main targets is XBP1, a member of the CREB/ATF family of transcription factors [7] [8] [9] [10] . IRE1 cleaves fulllength Xbp1 mRNA to initiate the removal of a 26-bp intron, thereby converting the unspliced XBP1 protein (XBP1u) to the highly active spliced form (XBP1s), which functions as a master regulator of ER folding capacity [1] [2] [3] [4] [11] [12] [13] [14] . Despite the crucial importance of XBP1s in several different cellular processes, and despite its association with a number of diseases, little is known about how this transcription factor is regulated 3, 4, [15] [16] [17] [18] [19] [20] [21] [22] [23] .
We and others have previously shown that obesity leads to the development of ER stress and activates the UPR in the liver, in adipose tissue and in the brain of mice [15] [16] [17] [18] 24, 25 ; this, in turn, contributes to the development of insulin resistance, type 2 diabetes and leptin resistance. We have also shown that nuclear translocation of Xbp1s is severely reduced in the liver of obese mice compared with lean mice, as a result of the loss of interactions between Xbp1s and the p85 regulatory subunits 26 . These results indicate that obesity actually creates an Xbp1s-deficient condition in the liver. If Xbp1s is reactivated in the liver by forced ectopic expression in severely obese and diabetic mice, blood glucose levels are reduced to euglycemia 27 .
p38 MAPK belongs to a family of evolutionarily conserved serine-threonine MAPKs that link extracellular signals to intracellular machinery regulating a plethora of cellular processes [28] [29] [30] [31] . c-Jun amino-terminal kinase (JNK) and p38 MAPK are described as stress-activated protein kinases (SAPKs). JNK and p38 MAPK are both activated by environmental and genotoxic stress, and both have key roles in converting extracellular stimuli into a wide range of cellular responses [28] [29] [30] [31] .
ER stress and UPR signaling also activate SAPKs, including JNK (ref. 32 ) and p38 MAPK (ref. 33); both signaling pathways are considered to be detrimental, and participate in the development of ER stress-related pathologies 34 , especially under conditions in which the cell can no longer cope with ER stress. The main aim of UPR signaling is to re-establish ER homeostasis. However, the ER is a dynamic organelle, with the capacity to respond rapidly to changes in the environment. For example, UPR transcription factors such as ATF6, XBP1 or ATF4 are rapidly activated to re-establish equilibrium within the ER. Of note in the context of this study, however, is the fact that the time frame of activation of these detrimental pathways is similar to that of the activation of the protective pathways. Notably, initiation of apoptosis occurs much later than this initial activation of UPR signaling parameters 35 . This temporal overlap between the activation of the SAPKs and that of the protective pathways, and the occurrence of cellular pathology in a later time frame, prompted us to investigate whether SAPK signaling also has positive effects on ER homeostasis via the regulation of UPR signaling elements.
Here we show that p38 mitogen-activated protein kinase (p38 MAPK) phosphorylates the spliced form of X-box binding protein 1 (Xbp1s) on its Thr48 and Ser61 residues and greatly enhances its nuclear migration in mice, whereas mutation of either residue to alanine substantially reduces its nuclear translocation and activity. We also show that p38 MAPK activity is markedly reduced in the livers of obese mice compared with lean mice. Further, we show that activation of p38 MAPK by expression of constitutively active MAP kinase kinase 6 (MKK6Glu) greatly enhances nuclear translocation of Xbp1s, reduces endoplasmic reticulum stress and establishes euglycemia in severely obese and diabetic mice. Hence, our results define a crucial role for phosphorylation on Thr48 and Ser61 of Xbp1s in the maintenance of glucose homeostasis in obesity, and they suggest that p38 MAPK activation in the livers of obese mice could lead to a new therapeutic approach to the treatment of type 2 diabetes. a r t i c l e s 1 2 5 2 VOLUME 17 | NUMBER 10 | OCTOBER 2011 nature medicine
RESULTS

SAPK signaling increases Xbp1s activity
To investigate whether activation of JNK or p38 MAPK affects Xbp1s activity, we expressed mouse Xbp1s in mouse embryonic fibroblasts (MEFs) by infecting them with Xbp1s-expressing adenovirus (AdXbp1s), or with LacZ-expressing adenovirus (Ad-LacZ; control). Subsequently, we treated the cells with increasing doses of anisomycin, an agent that activates JNK and p38 MAPK, for 2 h. Anisomycin treatment led to a robust increase in Xbp1s protein levels (Fig. 1a) , but only in cells infected with Ad-Xbp1s. We noted no upregulation of Xbp1s protein in Ad-LacZ-infected control cells treated with up to 25 ng ml −1 anisomycin, thus showing that anisomycin by itself does not create ER stress, nor does it induce Xbp1 splicing (Fig. 1a) . A time-course experiment demonstrated that exposure of the Xbp1s-expressing cells to anisomycin (25 ng ml −1 ) leads to upregulation of Xbp1s protein within the first 30 min (Fig. 1b) . To determine whether an alternative way of activating SAPKs would also increase Xbp1s protein levels, we treated the Xbp1s-expressing cells with increasing doses of tumor necrosis factor (TNF)-α for 2 h; as was the case with the anisomycin, TNF-α stimulation markedly increased Xbp1s protein amounts (Fig. 1c) . Our time-course study revealed that TNF-α (10 ng ml −1 ) also upregulates Xbp1s within 30 min (Fig. 1d) . Finally, by undertaking the same experiment in Fao cells, a rat hepatoma cell line, we produced similar results ( Supplementary Fig. 1a,b) . We next investigated whether upregulation of Xbp1s is due to an increase in protein stability. We infected cells with Ad-Xbp1s, subsequently treated them with vehicle (DMSO) or anisomycin (25 ng ml −1 ) for 2 h, and then further treated them with cycloheximide (10 µg ml −1 ) for the indicated time points to inhibit translation initiation; we determined Xbp1s levels before and after addition of cycloheximide (Fig. 1e,f) . To analyze the degradation rate of Xbp1s in vehicle-or anisomycin-treated cells correctly, we specifically exposed blots from vehicle-treated cells for a longer time and anisomycin-treated cells for a shorter time to achieve the same level of Xbp1s signal at the zero time points of both groups. We observed no differences in the degradation rate of Xbp1s protein in the vehicle-or anisomycin-treated cells (Fig. 1e,f) . These results exclude the possibility that anisomycin increases the amount of Xbp1s protein by increasing its stability.
However, we noted a substantial increase in mRNA levels of Xbp1s in the cells treated with anisomycin for 1 h (Fig. 1g) . To evaluate the possibility that anisomycin treatment increases the stability of Xbp1s mRNA, we pretreated the Xbp1s-expressing cells with anisomycin (25 ng ml −1 ) for 1 h and examined the degradation pattern of Xbp1s mRNA after inhibition of transcription with actinomycin D (10 µg ml −1 ). Anisomycin extended the half-life of the mRNA from around 15 min to 60 min (Fig. 1h) . Furthermore, we also found that nuclear levels of Xbp1s protein in anisomycin-treated (25 ng ml −1 , 2 h) cells were 141.8 times higher than in vehicle-treated cells, but cytoplasmic levels were only increased 28.8 times (Fig. 1i) . Under normal conditions, the fold increase in Xbp1s protein should be similar in the cytoplasmic and nuclear compartments. The fivefold discrepancy in these values prompted us to consider the notion that the anisomycin may increase the efficiency of nuclear translocation of Xbp1s. Taken together, the results presented to this point suggest that SAPK signaling increases the mRNA stability of Xbp1s and leads to higher-efficiency nuclear translocation.
To unravel the molecular mechanisms underlying the above observations, we took several different approaches to explore whether activation of JNK, which is one of the dominant signaling elements in SAPK signaling, affects Xbp1s levels and nuclear translocation. First, Ad-LacZ-and Ad-Xbp1s-infected MEFs were treated with a JNK inhibitor (10 µM, 30 min) and then exposed to anisomycin (25 ng ml −1 , 2 h). The JNK inhibitor was effective in completely abolishing anisomycin-induced JNK activation (Fig. 2a) , but it had no effect on 
Ad-LacZ Ad-Xbp1s anisomycin-mediated upregulation of Xbp1s protein (Fig. 2a) . As a second approach we used JNK1-and JNK2-deficient MEFs (Mapk8 −/− ; Mapk9 −/− ) and showed that stimulation of Mapk8 −/− ; Mapk9 −/− cells with anisomycin for 2 h also led to a robust increase in Xbp1s protein (Fig. 2b , left) compared with anisomycin-treated congenic wild-type cells (Fig. 2b, left) . Although no JNK activity was detectable in the Mapk8 −/− ; Mapk9 −/− cells that we treated with anisomycin, we did note a marked increase in p38 MAPK phosphorylation (Fig. 2b, left) . It is known that MKK4 and MKK7 are upstream kinases responsible for JNK activation 36, 37 , and that anisomycin or TNF-α cannot activate JNK in MKK4 and MKK7 double-knockout MEFs (Map2k4 −/− ; Map2k7 −/− ) 36, 38 . We thus assessed whether Xbp1s can be regulated by anisomycin treatment in Map2k4 −/− ; Map2k7 −/− cells; we treated these cells, along with their wild-type counterparts, with anisomycin for 2 h after Xbp1s expression. We found that, as in the Mapk8 −/− ; Mapk9 −/− cells, anisomycin stimulation markedly increased Xbp1s levels in Map2k4 −/− ; Map2k7 −/− cells to an amount higher than that observed in wild-type cells (Fig. 2b, right) . JNK activity was not detectable in the Map2k4 −/− ; Map2k7 −/− cells, whereas p38 MAPK activation was markedly increased (Fig. 2b, right) . Furthermore, we repeated the experiments in Mapk8 −/− ; Mapk9 −/− and Map2k4 −/− ; Map2k7 −/− cells with TNF-α; as with anisomycin, treatment of Mapk8 −/− ; Mapk9 −/− and Map2k4 −/− ; Map2k7 −/− cells with TNF-α also led to a robust increase in Xbp1s levels ( Supplementary Fig. 2a,b) . Finally, we used an MKK7-JNK1 fusion protein, previously shown to be a specific activator of the JNK pathway 39 , and we investigated whether the activation of JNK alone can affect Xbp1s protein levels. MKK7-JNK1 expression in the cells markedly increased JNK activity (Fig. 2c) . However, coexpression of MKK7-JNK1 with Xbp1s did not increase Xbp1s protein levels (Fig. 2c) . p38 MAPK is another crucial SAPK signaling element that is activated during ER stress conditions; also, in the absence of JNK activation, we noted higher levels of p38 MAPK activation ( Fig. 2b and Supplementary Fig. 2a,b) . We thus tested the possibility that p38 MAPK activation mediates the effects of anisomycin and TNF-α on Xbp1s. Ad-Xbp1s-infected MEFs were treated with a specific p38 MAPK inhibitor (SB203580, 10 µM) for 30 min and then stimulated with anisomycin (25 ng ml −1 ) for 2 h. We found that this treatment completely abolished Xbp1s protein increases (Fig. 2d) .
MKK3 and MKK6 are required for p38 MAPK activation, and, in fact, p38 MAPK cannot be activated in MKK3-and MKK6-deficient (Map2k3 −/− ; Map2k6 −/− ) MEFs 40 . In light of this, we reasoned that anisomycin should not induce an increase in Xbp1s levels in Map2k3 −/− ; Map2k6 −/− cells. Indeed, we noted no increase, relative to anisomycin-stimulated congenic wild-type cells, in Xbp1s levels when Ad-Xbp1s-infected Map2k3 −/− ; Map2k6 −/− cells were treated with anisomycin for 2 h (Fig. 2e, left) . Also, as previously reported 40 , we found that p38 MAPK activation was substantially reduced in Map2k3 −/− ; Map2k6 −/− cells (Fig. 2e, left) . We also showed that Ad-Xbp1s-infected p38-α-deficient (Mapk14 −/− ) cells lack the ability to upregulate Xbp1s in response to 2 h-anisomycin stimulation (Fig. 2e, right) . MKK6Glu, a constitutively active form of MKK6, was previously generated by mutation of Ser207 and Ser211 to glutamate 41 . Expression of MKK6Glu specifically activates p38 MAPK (ref. 41) . We used MKK6Glu to assess whether activation of p38 MAPK alone is sufficient to increase Xbp1s protein levels. Cells were first transfected with MKK6Glu and/or Xbp1s in the presence or absence of SB203580 (10 µM) for 24 h. Expression of MKK6Glu markedly increased Xbp1s protein levels, and the inhibition of p38 MAPK activity blocked the effect of MKK6Glu on Xbp1s protein levels (Fig. 2f) .
To investigate whether the increased stability of Xbp1s mRNA was indeed mediated via the p38 MAPK pathway, we pretreated cells first with SB203580 (10 µM, 30 min), treated them with anisomycin (25 ng ml −1 , 1 h), and finally incubated them with actinomycin D (10 µg ml −1 ) for indicated time points. Inhibition of p38 MAPK completely blocked the prolongation of the half-life of Xbp1s mRNA that was induced by anisomycin stimulation (Fig. 2g) .
p38 MAPK signaling has also been implicated in the regulation of the stability of several different mRNAs 42 . One of the main molecules linking p38 MAPK activation to the regulation of mRNA stability is MAPK-activated protein kinase 2 (MK2) (ref. 42) . MK2 was previously shown to regulate activation of several RNA-binding proteins that are involved in stabilization of mRNA 42 . These include tristetraprolin (TTP), human antigen R (HuR) and AU-rich element (ARE)/poly(U)-binding degradation factor (AUF1). In addition, p38 MAPK can also regulate RNA stability by directly phosphorylating KH-type splicing regulatory protein (KSRP) (ref. 42) .
To investigate whether the p38 MAPK-mediated increase in mRNA stability of Xbp1s is due to MK2 activation, we stimulated Ad-Xbp1s-infected congenic wild-type and MK2-deficient (Mapkapk2 −/− ) MEFs with anisomycin for 2 h; Xbp1s protein levels were considerably reduced in Mapkapk2 −/− cells, indicating that increased mRNA stability is primarily mediated via MK2 activation (Fig. 2h) . We next examined the mRNA levels of Xbp1s in wild-type and Mapkapk2 −/− cells that were infected with Ad-Xbp1s and stimulated with anisomycin for 1 h. We found that anisomycin increases the mRNA levels of Xbp1s in a dose-dependent manner in wild-type cells (Fig. 2i) , but the increase was significantly lower (P < 0.001) in the Mapkapk2 −/− cells (Fig. 2i) , thus supporting a dominant role for MK2 in p38 MAPK-mediated upregulation of Xbp1s mRNA stability. Furthermore, our analysis of degradation rate of Xbp1s mRNA in wild-type and Mapkapk2 −/− cells, that were pretreated with either vehicle or anisomycin (25 ng ml −1 , 1 h) and treated with actinomycin D (10 µg ml −1 ) for the indicated time points, showed that there were no differences in the degradation rate of Xbp1s mRNA between vehicle-treated wild-type and Mapkapk2 −/− and anisomycin-treated Mapkapk2 −/− cells (Fig. 2j) .
To investigate whether TTP might have a role in stabilizing Xbp1s mRNA, we treated Ad-Xbp1s-infected TTP-knockout (Zfp36 −/− ) cells with anisomycin, and then analyzed them for mRNA degradation after adding actinomycin D. Our results show that anisomycin is capable of increasing Xbp1s mRNA stability even in Zfp36 −/− cells (Supplementary Fig. 3a,b) .
To investigate the role of AUF1 and KSRP in stabilizing Xbp1s mRNA, we chose the most efficient shRNA for AUF1 and KSRP ( Supplementary Fig. 3c,e) and showed that depletion of AUF1 or KSRP does not affect anisomycin-induced upregulation of Xbp1s levels ( Supplementary Fig. 3d,f) . Finally, we sought to investigate the role of HuR in this process, but we could not detect expression of HuR in MEF cells (data not shown).
Despite these efforts, we were unable to identify the RNA-binding protein that is regulated by MK2 and that is responsible for increasing the stability of Xbp1s mRNA, leading us to conclude that another RNA-binding protein, which is an (as yet) unknown target of MK2, may be responsible for stabilizing Xbp1s mRNA. Further investigation is needed to determine the identity of this factor.
p38 MAPK phosphorylates Xbp1s on Thr48 and Ser61
The greatly increased migration efficiency of Xbp1s to the nucleus when p38 MAPK is activated was a notable result (Fig. 1i) , and prompted the hypothesis that p38 MAPK directly phosphorylates Xbp1s and thus triggers this enhanced translocation. To test this hypothesis, we expressed a Flag-tagged Xbp1s in MEFs and stimulated them with anisomycin (25 ng ml −1 ) for 2 h. Analysis by tandem mass spectrometry (MS/MS) showed that anisomycin stimulation increases phosphorylation of Xbp1s at Ser61, which is a conserved phosphorylation site (LSPE) for p38 MAPK (Fig. 3a) . One other phosphorylation site (Thr48) on Xbp1s is also a conserved p38 MAPK phosphorylation site, although we did not detect it by MS/MS analysis. To convincingly show that Ser61 is indeed phosphorylated after anisomycin stimulation or via activation of p38 MAPK, and also to test whether Thr48 is also a phosphorylation site, we developed a phospho-specific antibody against phosphorylated Xbp1s on Ser61 or on Thr48. We found that, in fact, stimulation of Xbp1s-expressing cells with anisomycin (25 ng ml −1 , 2 h) greatly increased phosphorylation of the Thr48 residue compare with the vehicle (DMSO)-treated cells (Fig. 3b) . To clarify the role of this phosphorylation site, we mutated the Thr48 residue to alanine (T48A) and showed that this completely eliminated the anisomycin-induced Thr48 phosphorylation of Xbp1s, but it did not affect the upregulation in Xbp1s protein levels (Fig. 3b) . We obtained similar results from Xbp1s Ser61 phosphorylation; 2-h anisomycin (25 ng ml −1 ) stimulation strongly induced phosphorylation of Xbp1s at Ser61, but mutation of Ser61 to alanine (S61A) did not alter the anisomycin-induced upregulation of Xbp1s protein levels (Fig. 3c) .
To determine whether p38 MAPK can directly phosphorylate Xbp1s, we produced a His-TF-Xbp1s fusion protein (Fig. 3d) and carried out an in vitro kinase assay with an already activated recombinant p38-α MAPK protein; revealing increased phosphorylation of Xbp1s (Fig. 3e) ; however, addition of SB203580 (10 µM) to the kinase assay buffer completely reversed the effect of activated p38 MAPK on Xbp1s (Fig. 3e) . As a positive control, the p38 MAPK kinase assay was also done with ATF2 (Fig. 3e) . In addition, we did an in vitro kinase assay followed by direct immunoblotting with use of the phosphospecific antibodies for p-Xbp1s Thr48 and p-Xbp1s Ser61 , which showed that p38 MAPK can directly phosphorylate Xbp1s on Thr48 and Ser61 residues in this assay (Fig. 3f) .
To understand the role of these phosphorylations, and to exclude a possible overlapping function in regulation of Xbp1s activity and nuclear translocation, we created mutant Xbp1s at Thr48 and/or Ser61 residues by converting these residues to alanine. We then investigated the contribution of each phosphorylation site on the nuclear translocation of Xbp1s. We expressed wild-type, T48A, S61A and T48A-S61A mutant Xbp1s in HEK293 cells, added anisomycin (25 ng ml −1 ) for 2 h and then determined total levels of cytoplasmic and nuclear Xbp1s proteins. We found that mutation of Thr48, of Ser61, or of both sites together did not affect the anisomycin-stimulated upregulation of Xbp1s protein levels (Fig. 3g) . However, mutation of the Thr48 residue decreased Xbp1s nuclear translocation by about 49%, mutation of the Ser61 residue by about 79%, whereas mutation of both sites markedly decreased nuclear translocation of Xbp1s compared with the WT Xbp1s (Fig. 3g) . In addition, mutation of Thr48 and Ser61 led to accumulation of Xbp1s in the cytoplasm, indicating that the double-mutant Xbp1s, despite its substantial increase in protein levels, cannot migrate to the nucleus (Fig. 3g) . These findings indicate that Thr48 and Ser61 phosphorylation is crucial for nuclear translocation of Xbp1s (Fig. 3g). p38 MAPK is crucial for Xbp1s activity during refeeding We have previously shown that Xbp1s is generated in the liver when mice are refed after a fasting period 26 . To create a metabolic overloading model in cells similar to in vivo fasting-refeeding, we incubated cells with medium containing 10% (vol/vol) FBS after they were maintained for a 16-h starvation period in medium without FBS. We observed a marked increase in Xbp1s splicing and nuclear translocation, as well as in activation of p38 MAPK, after re-stimulation with 10% (vol/vol) FBS when compared with the cells that were not stimulated with FBS (Supplementary Fig. 4a) . However, inhibition of p38 MAPK activity by pretreatment of the starved cells with SB203580 before addition of 10% (vol/vol) FBS, when compared with the cells that were not stimulated with FBS, strongly reduced Xbp1s nuclear translocation without altering Xbp1s splicing and without affecting the total amount of Xbp1s that is produced in the cells (Supplementary Fig. 4a) . We then did the same experiment again, but in Mapk14 −/− and Map2k3 −/− ; Map2k6 −/− cells. We found that FBS-induced Xbp1s nuclear translocation is substantially reduced in Mapk14 −/− and Map2k3 −/− ; Map2k6 −/− cells compared with wild-type cells, despite the fact that Xbp1s splicing and protein levels in both cell lines were similar to what we observed in their wild-type cells (Supplementary Fig. 4b,c) .
Our next step was to determine whether refeeding after a fasting period induces p38 MAPK activation and Xbp1s phosphorylation in the liver of lean wild-type mice. We fasted 8-week-old wild-type lean male mice for 24 h and refed them for 1 h; p38 MAPK phosphorylation was greatly increased in the liver following refeeding, and Xbp1s total proteins were upregulated (Fig. 4a) ; also, phosphorylation of Xbp1s at Thr48 and Ser61 was markedly increased after refeeding, indicating that Xbp1s is phosphorylated at these sites during the refeeding process (Fig. 4a) .
We also wanted to know how p38 MAPK signaling is regulated in obese mice, as we have previously shown that Xbp1s cannot migrate to the nucleus in the liver of obese mice during refeeding 26 . We found that refeeding of 8-week-old ob/ob male mice after the fasting period does not increase p38 MAPK phosphorylation (Fig. 4b) . Xbp1s levels in total lysates are increased in the livers of refed ob/ob mice compared with fasted controls, but there is no detectable phosphorylation of Thr48 and Ser61 in Xbp1s and no detectable Xbp1s protein in the nucleus (Fig. 4b) .
To examine whether inhibition of p38 MAPK signaling alone blocks Xbp1s nuclear translocation in the mouse, we treated 8-weekold wild-type lean male mice for 3 d either with vehicle (DMSO) or with SB203580 (2 mg kg −1 per day), after which the mice were starved for 24 h and refed for 1 h. Xbp1s nuclear levels greatly increased after refeeding in the vehicle-treated control group. However, Xbp1s nuclear translocation in the liver of SB203580-treated mice after refeeding was substantially reduced (Fig. 4c) . Analysis of ATF2 phosphorylation revealed a marked reduction, indicating that SB203580 successfully blocked the activation of p38 MAPK (Fig. 4c) . Xbp1s mRNA levels in the liver of refed mice that were either treated with vehicle or with the inhibitor were significantly increased in both groups (P < 0.001) (Fig. 4d) . Further analysis of mRNA levels of the Xbp1s target gene Hspa5 (heat shock protein 5, encoding the 78-kDa glucose-regulated protein, GRP78) revealed that Hspa5 expression was significantly increased in the vehicle-treated (P < 0.01), but not in the inhibitortreated group (Fig. 4e) . In addition to comparing fasting and refeeding states, we also investigated the basal p38 MAPK activity in the liver, muscle and white adipose tissue (WAT) of lean and obese mice. We found that p38 MAPK phosphorylation was markedly reduced in the liver, muscle and adipose tissues of ob/ob and high-fat diet (HFD)-fed obese mice, when compared with their lean counterparts ( Fig. 5a and Supplementary  Fig. 5 ). Previous observations have also indicated that p38 MAPK phosphorylation is reduced in the liver tumors of obese mice 43 .
Activation of p38 MAPK in the liver regulates blood glucose To determine whether reactivation of p38 MAPK in the livers of obese and diabetic mice would increase Xbp1s phosphorylation, reduce ER stress, increase glucose tolerance and reduce blood glucose levels, we produced MKK6Glu-expressing adenovirus (Ad-MKK6Glu) (Fig. 5b) . Next, 8-week-old ob/ob mice were injected through the tail vein with either Ad-MKK6Glu (n = 5) or Ad-LacZ (n = 5) (8 × 10 6 plaqueforming units (PFU) g −1 for each adenovirus). We found that 6-h fasting blood glucose levels on day 3 after adenovirus injections were significantly reduced (P < 0.01) in the Ad-MKK6Glu-injected group compared with the Ad-LacZ-injected control mice (Fig. 5c, left) . We noted significant reduction (P < 0.01) in the circulating insulin levels at the 6-h fasted state of the MKK6Glu-overexpressing ob/ob mice on day 7 after virus injections, indicating that insulin sensitivity is increased compared with controls (Fig. 5c, right) . Moreover, as documented by a glucose tolerance test (GTT) on day 5 after injection, the glucose disposal rate in the Ad-MKK6Glu-injected group was markedly enhanced when compared with the Ad-LacZ-injected group (Fig. 5d ). An insulin tolerance test (ITT) on day 3 after injection also revealed increased insulin sensitivity in the Ad-MKK6Glu-injected group (Fig. 5e) .
Furthermore, analysis of liver samples from Ad-LacZ-and AdMKK6Glu-injected ob/ob mice fasted for 6 h on day 7 after injection showed that p38 MAPK phosphorylation and downstream signaling were substantially increased in the MKK6Glu-expressing ob/ob mouse livers (Fig. 5f) . We found that Xbp1s total protein levels, nuclear protein levels, and Thr48 and Ser61 phosphorylations were markedly upregulated when MKK6Glu was expressed in the liver of ob/ob mice (Fig. 5g) . mRNA levels of Xbp1s, and expression of Hspa5 and Dnajb9 (DnaJ (Hsp40) homolog, subfamily B, member 9, encoding Dnajb9, also known as ERdj4; also another Xbp1s target gene) was also significantly elevated (P < 0.001), indicating increased Xbp1s mRNA stability and activity (Fig. 5h, top) . We next analyzed IRE1-α phosphorylation levels as indicative of ER stress and found it was markedly reduced in MKK6Glu-expressing ob/ob mouse livers (Fig. 5h, bottom) .
To investigate insulin sensitivity, we infused insulin (0.75 IU kg −1 ) into the livers of the Ad-LacZ-and Ad-MKK6Glu-injected ob/ob mice on day 7 after virus injections and analyzed the activation of insulin receptor, insulin receptor substrate 1 (IRS1) and Akt. We saw no differences between the two groups in terms of insulin-stimulated tyrosine phosphorylation of the insulin receptor, but we observed significant increases in IRS1 tyrosine and Akt Thr308 phosphorylations (P < 0.05) (Fig. 5i) . Furthermore, our analysis of the expression of genes such as glucokinase (encoded by Gck), glucose-6-phosphatase (encoded by G6pc), phosphoenolpyruvate carboxykinase 1 (encoded by Pck1) and peroxisome proliferator-activated receptor-γ coactivator 1-α (encoded by Ppargc1a), all of which are involved in glucose homeostasis, revealed a significant downregulation (P < 0.001) when MKK6Glu was expressed in the livers of the ob/ob mice (Fig. 5j) .
We also determined the extent of MKK6Glu expression in other tissues such as muscle and WAT after tail vein injection of the adenoviruses. The only marked increase in the expression of MKK6Glu was observed in the liver (Supplementary Fig. 6a ). In addition LacZ expression in the liver by tail vein injection of Ad-LacZ did not affect the blood glucose levels of ob/ob mice (Supplementary Fig. 6b) . Furthermore, tail vein injection of either Ad-LacZ or Ad-MKK6Glu did not alter the body weight and also did not lead to increase in liver function tests such as aspartate transaminase (AST) and alanine transaminase (ALT) tests in the ob/ob mice (Supplementary Fig. 6c,d) .
To determine the role of Xbp1s in MKK6Glu-mediated enhancement of glucose homeostasis, we overexpressed MKK6Glu in the liver of 16-week HFD-fed Xbp1 flox/flox mice, while simultaneously depleting Xbp1 with the use of an adenovirus that expresses Cre recombinase (Ad-Cre). The first group of mice was injected with Ad-LacZ, the second group with Ad-MKK6Glu plus Ad-LacZ, and the third group Figure 4 Inhibition of p38 MAPK blocks Xbp1s nuclear translocation. (a,b) Eight-week-old wild-type (WT) lean male mice (a) or age-matched ob/ob males (b) were fasted for 24 h and refed for 1 h. p-Xbp1s Thr48 , p-Xbp1s Ser61 , Xbp1s, p-p38, p38 and tubulin levels in total extracts and Xbp1s and lamin A/C protein levels in nuclear extracts of the liver. (c-e) Eight-week-old WT lean male mice were injected i.p. with SB203580 (2 mg kg −1 per day) for 3 d. Subsequently, mice were fasted for 24 h and refed for 1 h. (c) p-Xbp1s Thr48 , p-Xbp1s Ser61 , Xbp1s, p-ATF2 and tubulin levels in total extracts and Xbp1s and lamin A/C protein levels in nuclear extracts of the liver. (d,e) Xbp1s (d) and Hspa5 (e) mRNA levels at fasting and refed conditions in the livers of the mice either treated with vehicle or SB203580. We used Rn18s was used for normalization of gene expression. We used tubulin as a loading control for whole cell lysates and lamin A/C for nuclear lysates. Each experiment was independently reproduced three times. Error bars are ± s.e.m. **P < 0.01, ***P < 0.001, Student's t test. NS, Nonsignificant. #, nonspecific band. a r t i c l e s nature medicine VOLUME 17 | NUMBER 10 | OCTOBER 2011 1 2 5 7
was injected with Ad-MKK6Glu and Ad-Cre. Similar to the results obtained from the experiments on the ob/ob mice, we found that injection of Ad-MKK6Glu into the Xbp1 flox/flox mice led to a significant decrease in blood glucose levels (P < 0.05) (Supplementary Fig. 7a) . However, injection of Ad-Cre together with Ad-MKK6Glu eliminated the effect of MKK6Glu on blood glucose levels, indicating that Xbp1s has a major role in the improved glucose homeostasis mediated by MKK6Glu expression in the liver (Supplementary Fig. 7a ). Next, we did a GTT; we found that glucose disposal from the circulation was markedly enhanced in the MKK6Glu-expressing Xbp1 flox/flox mice, whereas depletion of Xbp1 in the MKK6Glu-expressing mice reduced this effect (Supplementary Fig. 7b ). We also analyzed p38 MAPK activation and MKK6 levels and showed that p38 MAPK was greatly activated in all the MKK6Glu-expressing groups ( Supplementary  Fig. 7c ). Xbp1s nuclear translocation was markedly increased in the MKK6Glu expressing group, but it was completely eliminated in the group expressing MKK6Glu plus Cre recombinase ( Supplementary  Fig. 7c) . Furthermore, analysis of IRE1 phosphorylation revealed a significant downregulation (P < 0.05) in the MKK6Glu-expressing group; this downregulation was abolished in the group expressing MKK6Glu plus Cre recombinase (Supplementary Fig. 7d ). Next, we determined the expression of chaperones; MKK6Glu expression led to a significant upregulation in the expression of Hspa5 (P < 0.001) and Dnajb9 (P < 0.05) but this effect was diminished in the Xbp1s-depleted group (Supplementary Fig. 7e ). Finally, analysis of G6pc, Pck1 and Ppargc1a mRNA levels revealed that MKK6-mediated downregulation of these genes was lost in the Xbp1s-depleted mice (Supplementary Fig. 7f ).
On the basis of our results to this point, we hypothesized that the T48A-S61A double-mutant Xbp1s, when expressed in the liver of obese mice, should not translocate to the nucleus and should not have any effect on glucose homeostasis. To investigate whether this was true, 8-week-old male ob/ob mice were injected either with Ad-LacZ (n = 5) or Ad-Xbp1s (n = 5) or Ad-Xbp1s T48A-S61A (n = 5) (3.6 × 10 7 PFU g −1 for each) via the tail vein. Our analysis of blood glucose levels showed that blood glucose levels of Ad-Xbp1s-injected ob/ob mice were at euglycemia (Fig. 6a) . However, expression of T48A-S61A mutant Xbp1s had no effect on blood glucose levels (Fig. 6a) . GTT analysis revealed that mutation of Thr48 and Ser61 diminished the ability of Xbp1s to enhance glucose tolerance (Fig. 6b) . In agreement with our (f,g) MKK6, p-p38, p38, p-ATF2 and actin levels (f), total Xbp1s and tubulin as well as nuclear Xbp1s, p-Xbp1s Thr48 , p-Xbp1s Ser61 and lamin A/C levels (g) in liver. (h) Top, mRNA levels of Xbp1s, Hspa5 and Dnajb9; bottom, p-IRE1 Ser724 , total IRE1 and actin protein levels. We used Rn18s for normalization of gene expression, actin or tubulin as a loading control for whole cell lysates and lamin A/C for nuclear lysates. (i) Insulin receptor (IR) and IRS1 tyrosine and Akt Thr308 phosphorylations, together with their total protein levels after insulin infusion. Graphs next to the blots depict the ratio between phosphorylated and total protein. IP, immunoprecipitation. (j) mRNA levels of Gck, Ppargc1a, G6pc and Pck1 in the livers. We used actin or tubulin as a loading control for whole cell lysates and lamin A/C for nuclear lysates. We used three independent groups of mice (n = 15 in each group). Error bars are ± s.e.m. Significance was determined by two-way ANOVA with Bonferroni multiplecomparison analysis (e) or Student's t test . *P < 0.05, **P < 0.01, ***P < 0.001.
recent observations 27 , moderate experimentally induced expression of Xbp1s in the liver did not alter insulin tolerance (Fig. 6c) . Nuclear Xbp1s was markedly increased in the livers of the Ad-Xbp1s-injected group, but there was no detectable mutant Xbp1s in the nuclear fractions of the livers of the Ad-Xbp1s T48A-S61A-injected group (Fig. 6d) . By analysis of total protein and mRNA levels of Xbp1s and Xbp1s T48A-S61A, we showed that both Xbp1s were similarly expressed in the liver (Fig. 6d,e) . Furthermore, upregulation of the chaperones, such as Hspa5 and Dnajb9, seen after Xbp1s expression, was diminished in the livers of ob/ob mice that expressed the mutant Xbp1s (Fig. 6f) . These results provide further evidence that, similarly to in vitro systems, phosphorylation of Xbp1s on T48/S61 is imperative for its function in vivo.
DISCUSSION
In recent years, we and others have shown that increased ER stress in obesity is a major link between obesity and type 2 diabetes [15] [16] [17] [18] and identified Xbp1 as a crucial factor for the maintenance of glucose homeostasis in obesity 17, 26, 27 . We have recently documented that a severe defect in the ability of Xbp1s to migrate to the nucleus is a central pathology for the development of ER stress in obesity 26 and that forced ectopic expression of Xbp1s in the liver of obese and diabetic mice greatly decreases ER stress, enhances glucose tolerance and reduces the blood glucose levels to euglycemia 27 . Together, these findings indicate that approaches that will increase Xbp1s activity could be an attractive therapeutic approach for the treatment of type 2 diabetes.
Our current work shows that p38 MAPK, a well-known SAPK, is an important regulator of Xbp1s nuclear translocation and activity. p38 MAPK increases the stability of Xbp1s mRNA and leads to marked protein upregulation. Furthermore, by phosphorylating Xbp1s on Thr48 and Ser61, p38 MAPK greatly enhances the nuclear translocation of this transcription factor. Mutation of the two phosphorylation sites leads to a substantial reduction in nuclear translocation of Xbp1s in vitro and in vivo. Although it is notable that phosphorylation of two residues can create such a pronounced effect on the efficiency of Xbp1s, the finding that preventing phosphorylation of Xbp1s almost completely blocks its activity was quite unexpected. Considering this potent effect of Thr48 and Ser61 phosphorylation on Xbp1s activity and the role of p38 MAPK in this process, we propose that p38 MAPK is a crucial element of UPR signaling and that it is required for maintenance of ER homeostasis via its effects on Xbp1s nuclear accumulation and thus its activity.
Furthermore, we have also shown that deficiency of JNK in the cells leads to enhanced p38 MAPK activation. Considering the fact that p38 MAPK activation leads to a great enhancement in glucose homeostasis, it is also possible that improvement seen in metabolic homeostasis in JNK-deficient mice could also be contributed by increased p38 MAPK signaling and consequently upregulated ER folding capacity.
The only known physiological condition in which Xbp1s is activated in the liver is during the refeeding (metabolic load) of mice after a fasting period. Using this condition as an experimental model, we have shown that inhibition of p38 MAPK with the use of different approaches (pharmaceutical or genetic) blocks the nuclear translocation of Xbp1s without affecting its splicing or total protein levels. We further showed that Xbp1s is phosphorylated on Thr48 and Ser61 in the liver of lean mice during refeeding, and it is then able to migrate to the nucleus. However, when obese mice are subjected to the same fasting and refeeding protocol, no such phosphorylation is evident and no Xbp1s is found in the nucleus. It is notable that p38 MAPK activation markedly increases in the livers of lean mice after refeeding, but this activation is not observed in obese mice. By putting this information together with the data showing that inhibition of p38 MAPK in lean mice blocks Xbp1s Thr48-Ser61 phosphorylation and nuclear translocation, we suggest that p38 MAPK activity is important for Xbp1s activity and its nuclear translocation in vivo.
Indeed, increasing p38 MAPK activity by expressing MKK6Glu in the liver of obese and diabetic mice substantially increases Xbp1s phosphorylation and nuclear translocation and markedly enhances glucose tolerance. In other words, activation of p38 MAPK converts the hyperglycemic state of ob/ob mice to a euglycemic state. This is an unexpected observation because the general view in the obesity and diabetes field leans toward the idea that, in general, SAPK signaling is detrimental to metabolic homeostasis [44] [45] [46] [47] [48] . The role of inflammation in development of insulin resistance and type 2 diabetes is currently an accepted hypothesis [44] [45] [46] [47] [48] . However, our results indicate that not all the inflammatory signaling pathways worsen glucose Figure 6 Xbp1s-T48A-S61A cannot migrate to the nucleus in the liver and regulate glucose homeostasis. (a-c) Six-hour fasting blood glucose levels on day 3 (a), GTT on day 5 (b) and ITT on day 7 (c) after adenovirus injections. (d) Xbp1s protein levels in the whole and nuclear liver extracts of the mice on day 9 after virus injections. (e,f) Xbp1s (e) and Hspa5 and Dnajb9 mRNA levels (f) in the liver. We used Rn18s for normalization of gene expression. We used tubulin as a loading control for whole cell lysates and lamin A/C for nuclear lysates. We used three independent groups of mice (n = 15 in each group). Error bars are ± s.e.m. Significance was determined by one-way ANOVA (except in c; two-way ANOVA) with Bonferroni multiple-comparison analysis. *P < 0.05, **P < 0.01, ***P < 0.001. NS, nonsignificant.
homeostasis in obesity. Despite the presence of an increased inflammatory state in obesity and increased activity of other inflammatory signaling cascades, such as the JNK pathway 49 , we find that p38 MAPK activity in the liver of obese mice is reduced compared with the nonobese mice, raising the possibility that p38 MAPK signaling pathway becomes resistant to cytokine signaling in obesity, as the p38 MAPK pathway is normally activated with various inflammatory signals, including TNF-α. It is possible that this unbalanced activation of inflammatory signaling pathways or development of cytokine resistance could have an important role in the development of various pathologies related to glucose homeostasis in obesity.
Our results provide indications that specific activators of p38 MAPK might help in the re-establishment of ER homeostasis and treatment of type 2 diabetes in obesity. The importance of Thr48 and Ser61 phosphorylation suggests that inhibition of the phosphatases that dephosphorylate Xbp1s could be a new approach for increasing Xbp1s activity. Furthermore, the link that we have identified between p38 MAPK and Xbp1s also has implications for diseases other than obesity and type 2 diabetes. For example, inhibition of Xbp1 activity in cancer cells that have large amounts of protein synthesis, such as multiple myeloma, could be a possible chemotherapeutic tool, something already observed for this type of cancer 50 . Our results suggest that inhibition of p38 MAPK activity (inhibitors for p38 MAPK already exist) could similarly be beneficial in cancers that have a substantial amount of protein synthesis. Our findings also add another dimension to the use of p38 inhibitors: p38 MAPK inhibition has been considered in the treatment of some inflammatory diseases, such as Crohn's disease, psoriasis and asthma 28 . These therapeutic approaches should, however, be evaluated within the context of our results, and in light of the possibility that inhibition of XBP1s activity may also decrease the ability of a cell to cope with inflammatory conditions 19, 20 .
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/.
